Tagged with Roche

Sweden Though far from the largest pharma market in Europe, Sweden nevertheless holds strategic importance for global pharma; from the country’s attitude to public health to its sophisticated digital framework, comprehensive patient registries and innovative spirit. Here, four pharma country managers hailing from outside Sweden’s borders give their first impressions of…

Sweden Amy Van Buskirk, general manager of Roche Sweden, discusses the role Roche plays in the Swedish healthcare system, how Sweden is becoming an innovation leader once more as well as a frontrunner in precision medicine, and explains how Roche wants to build strategic partnerships and form lasting relationships in order…

Spain Jaime Vives, managing director of Roche Diagnostics in Spain, discusses the digital solutions Roche Diagnostics is trying to roll out in Spain, the challenges involved, and the potential implications of digitalising healthcare   The first step into digitalization is to convince our customers to standardise their systems and the way…

Korea Nic Horridge was recently appointed president of Roche Korea, having spent an extended period in emerging Asian markets. He shares his vision for the Korean affiliate, focused on bringing Roche’s extensive global pipeline of innovative medicines to Korean patients, making personalized healthcare a reality in clinics and championing Korea as…

China China’s unbridled growth has spurred a vast number of overseas Chinese to return home to seek new opportunities in their transformed homeland. Affectionately known as ‘sea turtles’ because the Chinese characters for ‘returning from overseas’ are homonyms for the Chinese characters for ‘sea turtles’, this influx has ignited the country’s…

Egypt Mohamed Swilam, country manager of Roche Egypt, explains how ensuring access to medicine in Egypt is not only related to pricing challenges, but also to support healthcare systems, improve diagnosis, educate and build local skills. He also gives insights into the company’s plans on how to partner with stakeholders across…

Digitalization In an increasingly digitalised world, pharma companies are having to reconsider their communication strategies. Some, such as Swiss giant Roche, are turning to online webinars to better engage with healthcare practitioners (HCPs) across the globe.   Today’s doctors are time-crunched and digital-savvy, and they want targeted and relevant communication solutions…

Diversity Annually, PharmaBoardroom conducts hundreds of interviews with global CEO’s, country managers and industry leaders in the pharma industry. While we have crossed paths with many inspiring females in these positions, out of the top 50 pharma companies, only 3 are headed by women. That is a mere 6% — this…

China Hong Chow, general manager of Roche Pharma China, shares Roche China’s incredible milestones over the past few years, including four pivotal oncology drugs listed on the National Reimbursement Drug List (NRDL) in 2017; the company’s USD 129 million investment in a new innovation center in Shanghai, the third strategic innovation…

China China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats of blockbuster drugs in development, potentially difficult times lie ahead for Roche and other Big Pharma firms in China.  …

Top 10 The Top 10 bestselling orphan drugs in the USA in 2017. Celgene’s Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion, followed by Roche’s Rituxan (rituximab) with USD 4.2 billion in sales and TEVA’s Copaxone (glatiramer acetate) with USD 3.1 billion. The most expensive drug in…

Top 10 The top 10 companies in the world ranked by global orphan drug sales and market share in 2017. Swiss giants Novartis and Roche take the top two places, followed by American firm, Celgene. Made with Visme Infographic Maker